PART #1 Harnessing the power of preclinical studies with torasemide to inform a clinical dose LUDOVIC PELLIGAND, MATHIEU PEYROU See session
PART #1 Efficacy and safety of ISEMID® in dogs with first onset of congestive heart failure: the CARPODIEM and SAFEDIEM studies Mark Oyama See session
PART #2 Overcoming cardiorenal challenges to optimise heart failure management PATRICK ROSSIGNOL See session
PART #2 Panel discussion BERTRAM PITT, FRÉDÉRIC JAISSER, JONATHAN MOCHEL, LUDOVIC PELLIGAND, MARISA AMES, Mark Oyama, MATHIEU PEYROU, PATRICK ROSSIGNOL See session
